Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2020 | Translation into therapeutic strategies: the ADAR pathway

Jeffrey Ishizuka • 28 Sep 2020
ITOC 2020

Jeffrey Ishizuka, MD, DPhil, Yale School of Medicine, New Haven, CT, explains the challenges facing ADAR targeting. He suggests that a small molecule approach or genetically targeting ADAR could be a way to overcome immunotherapy resistance, but highlights that continuous research is needed in order to use ADAR inhibition as a therapeutic strategy. This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.

More from Jeffrey Ishizuka

Potential of ADAR pathway in immunotherapy
3:03
Potential of ADAR pathway in immunotherapy
Jeffrey Ishizuka • 28 Sep 2020
ADAR inhibition: patient stratification
1:21
ADAR inhibition: patient stratification
Jeffrey Ishizuka • 3 Nov 2020

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals